Sustained zero-order delivery of GC-1 from a nanochannel membrane device alleviates metabolic syndrome - Filgueira, C S; Nicolov, E; Hood, R L; Ballerini, A; Garcia-Huidobro, J; Lin, J Z; Fraga, D; Webb, P; Sabek, O M; Gaber, A O; Phillips, K J; Grattoni, A (International Journal of Obesity, 2016)
Keywords: 101/58; 13/51; 38/62; 38/77; 631/443/319/1642/393; 631/61/350; 631/61/54/152; 64/60; 692/163/2743/2037; 692/308/2778; 82/16; 96/63; Acetates - administration & dosage; Acetates - pharmacology; Acetates - therapeutic use; Adipose tissue; Adipose tissue (brown); Animals; Beta cells; Blood glucose; Body fat; Body weight; Body weight loss; Cholesterol; Compliance; Diabetes; Diabetes mellitus; Diet; Diet, High-Fat; Disease Models, Animal; Drug delivery; Drug delivery systems; Drug dosages; Epidemiology; Glucose; Health Promotion and Disease Prevention; Health services; High fat diet; House mouse; Inflammation; Inflammatory response; Insulin; Internal Medicine; Liver; Male; Medicine; Medicine & Public Health; Membranes; Metabolic Diseases; Metabolic disorders; Metabolic syndrome; Metabolic Syndrome - drug therapy; Metabolic Syndrome - metabolism; Metabolism; Mice; Mice, Inbred C57BL; Mice, Obese; Molecular Targeted Therapy; Nanochannels; Obesity; Obesity - drug therapy; Obesity - metabolism; original-article; Pancreas; Patient compliance; Phenols - administration & dosage; Phenols - pharmacology; Phenols - therapeutic use; Phosphates; Plasma levels; Prostheses and implants; Public Health; Research centers; RNA; Selectivity; Thyroid; Thyroid gland; Thyroid Hormone Receptors beta - agonists; Thyroid-stimulating hormone; Thyrotropin; Thyroxine; Transcription; Transplants & implants; Triglycerides; Weight control; Weight loss; United States--US